Ep Biocomposites has received a confirmed work order worth Rs 0.92 crore from Beleza by the Beach for the supply, installation, testing, and commissioning of a Sewage Treatment Plant.

Order In Financial Context

The disclosed order value of Rs 0.92 crore (Rs 92.04 lakh) is classified as "Significant" under regulatory norms, indicating its materiality to the company's current operational scale. Given that the Trailing 12-Month Revenue is reported as 0.0 Cr in the provided fundamental context, calculating a standard book-to-bill ratio or percentage of quarterly revenue is not analytically feasible using the provided data points; however, the order represents a firm contractual commitment. The total disclosed order book consists solely of this single contract, as no other orders were disclosed in the last three fiscal quarters. This single order constitutes the entirety of the visible backlog for the period analyzed.

Company Order Track Record

The company has not disclosed any other order wins in the last three fiscal quarters. The current order is the sole entry in the recent order history provided.

Note: The order date is listed as 30.04.2027. The inflow velocity is currently defined by this single disclosure.

Execution And Revenue Quality

The provided financial data indicates a Trailing 12-Month Revenue of 0.0 Cr and Net Profit of 0.0 Cr. Consequently, there is no historical quarterly revenue or OPM trend available in the input to assess execution quality against this new order. The absence of reported revenue in the TTM period suggests either a reporting lag, a specific accounting treatment not detailed here, or a period of minimal recognized revenue prior to this filing.

Revenue Growth - Order Wins Translating To Revenue

The standalone annual P&L data shows a mixed growth trajectory over the last five years. Revenue growth was +13.8% in FY26, following +3.2% in FY25 and +60.9% in FY24. Profit growth was +41.5% in FY26, recovering from -10.3% in FY25. The recent order win adds to the order book, but its impact on future annual revenue figures will depend on execution timelines and recognition policies which are not detailed beyond the completion date of April 30, 2027.

Working Capital And Execution Capacity

Data regarding Current Ratio, Total Liabilities/Equity, Operating Cashflow, and Free Cashflow is [data not available] in the provided input. Therefore, an assessment of liquidity to execute the project or the conversion of backlog into cash cannot be performed based on the supplied figures.

What To Watch

• Execution Timeline: The contract specifies a completion date of 30.04.2027. Monitor interim updates on mobilization and installation progress leading up to this deadline.
• Revenue Recognition: With TTM revenue at 0.0 Cr, watch for the first quarter where this order contributes to reported top-line numbers.
• Client Concentration: The single client, Beleza by the Beach, accounts for 100% of the disclosed order book in the last three quarters.
• Order Book Expansion: Monitor subsequent filings for additional order wins to assess if this is an isolated event or part of a broader pipeline recovery.

Key Observations

• Backlog signal: The total disclosed order book is Rs 0.92 crore, derived from a single contract. At this level, the binding constraint is the acquisition of further orders rather than capacity utilization.
• Valuation check (as of 26 Sep 2026): P/E of 11.1x against ROCE of 16.24%. The valuation appears to price in stability, though the low market cap of Rs 16.20 crore indicates high sensitivity to individual contract outcomes.
• Client concentration: A single client, Beleza by the Beach, accounts for 100% of the recently disclosed order inflow.

EP Biocomposites Limited has disclosed the draft Chairman's speech for its upcoming 7th Annual General Meeting, scheduled for September 28, 2026. The filing highlights a year of record financial performance and strategic expansion in water treatment and fire safety solutions.

The Goa-based engineering and manufacturing company reported revenue from operations of ₹1,363.98 lakh for FY26, up from ₹1,200.62 lakh in FY25. This represents a year-on-year increase of approximately 13.6%. The Chairman described FY26 as an important year where the company built capabilities for the future, noting that the financial figures represent the best performance in the company's history.

Financial Performance

The company’s profitability metrics showed improvement alongside top-line growth. Key financial figures for the fiscal year ending March 31, 2026 are outlined below:

Net profit for FY26 stood at ₹145.83 lakh, a significant rise from ₹103.08 lakh in the previous year. The profit after tax margin expanded to 10.69% from 8.49% in FY25.

Strategic Milestones and Partnerships

A key highlight of the year was the acquisition of the Bicholim factory premises, executed per shareholder approvals. The company also entered into a strategic collaboration with the Indian Institute of Science (IISc), Bengaluru, to strengthen capabilities in advanced wastewater treatment and sustainable recycling solutions.

The Chairman emphasized the growing importance of the Aqua business, which addresses the need for treating, recycling, and reusing wastewater. Notable project completions included contracts for ONGC and the Cutbona jetty. The company continues to leverage its association with DRDO for bio-digester systems, which have been included in the Goa State Pollution Control Board manual to drive adoption.

Business Operations

EP Biocomposites operates across three diversified verticals: Aqua (water treatment), Composites (FRP products), and Fire safety solutions. In FY26, the Aqua segment contributed the largest share of revenue at 49.45%, followed by FRP at 43.04% and Fire at 7.51%.

The company maintains a manufacturing facility in Goa with a capacity of 2.0 lakh sq. ft., operating at 70% utilization. It serves government and institutional clients, which accounted for 60% of its revenue mix in FY26. The Chairman noted that the company is focusing on expanding its geographical presence and strengthening its distribution network to cross-sell products across existing customers.

What the Numbers Show

EBITDA grew by nearly 26% to ₹237.83 lakh in FY26, outpacing the 13.6% revenue growth. This divergence indicates operational leverage, as the EBITDA margin widened by 174 basis points to 17.43%. Finance costs remained relatively stable at ₹33.99 lakh compared to ₹35.46 lakh in FY25, suggesting controlled interest expenses despite higher operations.